CLINICAL TRIAL: PHASE I/II STUDY OF SAFETY AND IMMUNOGENICITY OF QUADRIVALENT ME

临床试验：四价 ME 安全性和免疫原性的 I/II 期研究

• 批准号: 7950829
• 负责人: Sharon A Nachman
• 金额: $ 1.83万
• 依托单位: STATE UNIVERSITY NEW YORK STONY BROOK
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7950829
• 关键词: 11 year old; Bacteria; Clinical Research; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Conjugate Vaccines; Disease; Funding; Grant; HIV; Infection; Institution; Life; Meningitis; Meningococcal Infections; Names; Neisseria meningitidis; Phase; Research; Research Personnel; Resources; Risk; Safety; Source; United States National Institutes of Health; Vaccines; high risk; immunogenicity; safety study

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is being done to evaluate the safety and effect of MCV4 vaccine against meningococcal infections. It is recommended for people beginning at 11 years old. The full name of the vaccine is Quadrivalent Meningococcal Conjugate Vaccine (MCV4). Meningococci are bacteria that can cause Meningitis. Meningitis. is a disease that may be severe and even life threatening. Research has shown that 15-24 year olds are at high risk for infection from meningococci, and that HIV infected people may be at greater risk for this infection than healthy people. This vaccine cannot cause meningococci infection.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 中心，不一定是研究者的机构。 本研究旨在评估 MCV4 疫苗对抗脑膜炎球菌感染的安全性和效果。 建议从 11 岁开始使用。 该疫苗的全名是四价脑膜炎球菌结合疫苗（MCV4）。 脑膜炎球菌是可引起脑膜炎的细菌。 脑膜炎。是一种可能很严重甚至危及生命的疾病。 研究表明，15-24岁的人感染脑膜炎球菌的风险很高，而艾滋病毒感染者可能比健康人面临更大的感染风险。 该疫苗不会引起脑膜炎球菌感染。